As we enter the next phase of discovery in concussion science, the field continues to evolve from descriptive characterization toward mechanistic precision and personalized care. Over the past decade, concussion research – once dominated by symptom checklists and return-to-play guidelines – has matured into a multidisciplinary enterprise integrating neuroimaging, fluid biomarkers, computational modeling, and digital health tools. In 2024 and 2025 alone, more than 2,700 peer-reviewed papers include “concussion” in their title or abstract, underscoring the extraordinary expansion of this scientific frontier.
At Concussion, we have experienced an exciting and transformative period from 2024 through 2025. The journal is now proudly published under Aldus Press, an organization fully dedicated to advancing its growth and impact. Our manuscript submission and review process has been modernized through a new platform powered by Scholastica (available at concussion.scholasticahq.com), providing authors with a streamlined, transparent, and responsive experience.
As the new Editor-in-Chief, I am honored to lead Concussion at this pivotal moment. Together with Chief Publishing Officer Lyndsey Dixon (dixon@alduspress.com) and co-Founder Bas Straub (Straub@alduspress.com) at Aldus Press and Editorial Manager Jane Skelton (concussion@editorialoffice.co.uk) at Editorial Office, we are committed to ensuring that the journal remains a platform for rigorous science and thoughtful dialogue – bridging laboratory discovery with real-world application. Our strong and diverse Editorial Board continues to provide invaluable expertise and support, helping to guide the journal’s direction, maintain its high standards and connect the journal to its research community. Whilst we discuss the community we are invested in nurturing and developing new talent so if you are looking to become involved in the journal, we would welcome you as a reviewer or early career Editorial Board Member.
Concussion remains dedicated to accessibility and scientific equity. We maintain low publication fees while offering full open-access publication through our Gold e-publication model, ensuring that research is freely available to the global community. We anticipate that the journal will continue to attract a growing readership, reflecting the increasing public and professional awareness surrounding concussion science.
As the subject develops as does the journal, we continue to warmly welcome submissions spanning original research, systematic reviews, meta-analyses, clinical commentary, expert opinion, policy discussions, education-focused perspectives, case reports, and pilot studies. We are expanding our subject coverage to areas of particular interest including clinical and preclinical investigations, biomarker discovery for diagnosis and prognosis, pathogenesis and pathology, long-term outcomes, and concussion as it relates to sports medicine and broader neurological health. Several issues are in progress that will focus on emerging areas of study including concussion in intimate partner violence, the military, and biomarkers. We expect these to publish in the new year and invite researchers in these areas to consider us as a venue for your work.
As part of our continued outreach, we are excited to announce the launch of the new Concussion Newsletter, which will highlight emerging discoveries, significant developments, and newsworthy events in the field. The newsletter can be accessed through our newly redesigned homepage (https://concussion.scholasticahq.com/) or by following us on LinkedIn (https://www.linkedin.com/company/concussion-journal). We invite all researchers, clinicians, and members of the concussion community to join us in advancing this dynamic and rapidly evolving discipline.
Sincerely,
Kevin K. Wang, PhD, Editor-in-Chief, Concussion
Lyndsey Dixon, Chief Publishing Officer, Aldus Press
Bas Straub, co-Founder and Managing Director, Aldus Press
Jane Skelton, Managing Editor, Scholastica
Author contributions
KKW was involved in the review of the literature, writing, editing and approving the final version of the manuscript. LD, BS and JS were involved in editing or reviewing the draft manuscript.
Financial disclosure
LD & BS are associated with Aldus Press. No writing assistance was utilized in the production of this manuscript.
KKW is share-holder of Gryphon Bio, Inc., and share-holder of Owl Therapeutics.
Competing interests disclosure
KKW is Editor-in-Chief of Concussion. LD is Chief Publishing Officer for Aldus Press, BS is Managing Director of Aldus Press.
KKW is share-holder of Gryphon Bio, Inc., and share-holder of Owl Therapeutics.